Last year, M&A activity in the U.S. healthcare and life
sciences sector saw a decrease in both deal number and deal value
when compared with 2012. While 2012 saw 463 deals worth US$124
billion, 2013 saw 294 deals worth US$97 billion. Nevertheless,
according to the results of Mergermarket's Healthcare and Life Sciences
M&A Outlook optimism reigns for 2014.
The report, published June 30, believes M&A activity in the
healthcare subsector will rise as a result of increased regulation.
In particular, the report expects the Affordable Care Act
(ACA) to have a significant impact on M&A
activity among hospitals and healthcare providers. Because of the
ACA's shift away from a fee-for-service model and towards a
managed care delivery system, it is predicted that hospitals and
healthcare providers will look to consolidate to achieve economies
of scale. Furthering this push to achieve more productive,
cost-efficient systems are Medicare reimbursement cuts, and
readmission penalties. Consequently, it is anticipated hospitals
will demand facility and equipment improvements in as well as
greater IT support or capabilities.
In the life sciences subsector, the report expects M&A
activity to be significant among biotechnology/pharmaceutical
firms. Large pharmaceutical companies are currently undergoing a
period of decreasing sales and limited organic growth
opportunities. To address this, companies will look to consolidate
to improve their R&D development, and to gain access to new and
emerging markets and to new drug pipelines/niche products. This
trend began to play itself out in 2013 with Amgen's US$9
billion purchase of Onyx Pharmaceuticals, whereby Amgen obtained
full rights to a lucrative blood cancer drug.
Despite predicting an increased appetite for deal-making, the
report cautions as to the effect of regulatory change on closing.
New regulations have added complexity and have contributed to
greater scrutiny from enforcement agencies, thereby making
compliance more difficult. In response to these new challenges, it
is anticipated that buyers may obtain representations and
warranties insurance relating to the seller's compliance with
healthcare regulations. In an industry survey of would-be
deal-makers, 88% of respondents said they intended to obtain
representations and warranties insurance in 2014 compared with 44%
The author wishes to thank Michael Viner, summer
student, for his assistance in preparing this legal
Norton Rose Fulbright Canada LLP
Norton Rose Fulbright is a global legal practice. We provide
the world's pre-eminent corporations and financial institutions
with a full business law service. We have more than 3800 lawyers
based in over 50 cities across Europe, the United States, Canada,
Latin America, Asia, Australia, Africa, the Middle East and Central
Recognized for our industry focus, we are strong across all
the key industry sectors: financial institutions; energy;
infrastructure, mining and commodities; transport; technology and
innovation; and life sciences and healthcare.
Wherever we are, we operate in accordance with our global
business principles of quality, unity and integrity. We aim to
provide the highest possible standard of legal service in each of
our offices and to maintain that level of quality at every point of
Norton Rose Fulbright LLP, Norton Rose Fulbright Australia,
Norton Rose Fulbright Canada LLP, Norton Rose Fulbright South
Africa (incorporated as Deneys Reitz Inc) and Fulbright &
Jaworski LLP, each of which is a separate legal entity, are members
('the Norton Rose Fulbright members') of Norton Rose
Fulbright Verein, a Swiss Verein. Norton Rose Fulbright Verein
helps coordinate the activities of the Norton Rose Fulbright
members but does not itself provide legal services to
The content of this article is intended to provide a
general guide to the subject matter. Specialist advice should be
sought about your specific circumstances.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
Effective September 1, 2016, the Disposition of Surplus Real Property Regulation to the Ontario Education Act was amended with the intention to reduce barriers to the formation of health and community hubs in Ontario.
This appeal relates to two generic drug submissions for two different products: exemestane and infliximab. Both submissions cross-referenced the submission of another generic company that had received a Notice of Compliance.
Two recent decisions from the Supreme Court of Canada directly affect Quebec's farm businesses by confirming La Financière Agricole du Québec's discretion in the administration of the farm income stabilization program...
On October 6, 2016, the Ontario Legislature reintroduced the Patients First Act, 2016 as Bill 41. Bill 41 is very similar to its predecessor, Bill 210, which was introduced in June 2016, but makes some important changes to the previous bill.
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).